Loading...
•
Dec 31, 2024
Alector Q4 2024 Earnings Report
Alector reported its fourth quarter and full year 2024 financial results, showing a significant increase in collaboration revenue and a reduced net loss compared to the previous year.
Key Takeaways
Alector reported a strong fourth quarter in 2024, with collaboration revenue significantly increasing to $54.2 million from $15.2 million in the same period last year. The company also reduced its net loss to $2.1 million, or $0.02 per share, compared to a net loss of $41.4 million, or $0.49 per share, in Q4 2023. Cash, cash equivalents, and investments totaled $413.4 million, providing a runway through 2026.
Collaboration revenue for Q4 2024 increased significantly to $54.2 million, up from $15.2 million in Q4 2023.
Net loss for Q4 2024 was $2.1 million, a substantial improvement from a $41.4 million net loss in Q4 2023.
Cash, cash equivalents, and investments stood at $413.4 million as of December 31, 2024, providing financial runway through 2026.
The company anticipates topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN by Q4 2025.
Revenue by Segment
Forward Guidance
For the year ending 2025, Alector anticipates collaboration revenue between $5 million and $15 million, total research and development expenses between $175 million and $185 million, and total general and administrative expenses between $55 million and $65 million.
Positive Outlook
- Anticipated topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN by Q4 2025.
- Expected completion of enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 by mid-2025.
- Advancing preclinical and early research pipeline, including ADP037-ABC (anti-amyloid beta) and ADP050-ABC (GCase replacement therapy) towards IND-enabling studies.
- Plans to enter the clinic with ADP037-ABC and ADP050-ABC programs in 2026.
- Financial runway through 2026 with $413.4 million in cash, cash equivalents, and investments.
Challenges Ahead
- The INVOKE-2 Phase 2 clinical trial for AL002 (TREM2 agonist) did not meet its primary endpoint.
- Collaboration revenue guidance for 2025 ($5 million to $15 million) is significantly lower than 2024 actuals ($100.6 million), indicating a potential decrease in collaboration-related income.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...